All Articles

Breakwater and Aaru's new platform simulates 40,000 investors to give companies a 'decision advantage', shifting corporate strategy from reactive to predictive.

Recent SEC filings link powerhouse investor Citadel to streaming upstart FreeCast. But as we peel back the layers, a story of high-risk, high-reward emerges.

As LiveWire reports its Q2 results, it faces a paradox: soaring sales and market dominance against crippling losses and fleeing investors. Can it escape its parent's orbit?

A new study reveals the thriving, high-risk market for compounded weight-loss drugs. Even after FDA shortages ended, some clinics use unregulated suppliers.

L7 Informatics hires Ray Veeraraghavan, a former customer and world-record-holding AI architect, to bridge the chasm between AI promise and lab reality.

John and Ann Tickle's record-breaking donation to Ballad Health is more than charity; it's a strategic investment in a region's future and a model for rural wellness.

Toubani Resources’ 19.9% acquisition of Avanti Gold is more than a simple investment. It’s a calculated move that reshapes the African junior gold landscape.

Acrow's win at the NCE Bridges Awards highlights its innovative engineering and collaborative approach, cementing modular construction's role in global infrastructure.

PEO's latest distribution highlights strong performance and a key choice for investors, underscoring its 90-year legacy in a dynamic energy market.

With a $55M investment led by Bluestone Equity, the creators of Topgolf are aiming to revolutionize the $35B pool industry with their tech platform, BillyQ.

After years of losses, the micro-mobility sector has a rare success story. Dott's €20M EBITDA proves that disciplined strategy, not hype, wins the race.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

SSR Mining completes its strategic pivot to the Americas, trading its Hod Maden equity for a royalty stream and shedding geopolitical risk for free cash flow.

Arch Biopartners is fast-tracking a novel therapy for diabetic kidney disease, targeting IL-32 to address a massive unmet medical need for millions globally.

As Erie Indemnity prepares its Q2 results, the insurer faces a complex landscape of rising claims and hard-market dynamics. Will its stability hold?

With the launch of DentalOS, Planet DDS declares the practice management era over, betting on a unified, AI-driven platform to solve enterprise-scale challenges.

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

Shore Capital's sale of 102 vet clinics to FCPT isn't just a deal; it's a masterclass in using niche real estate to fuel growth and secure big returns.

As The Royal Canadian Legion marks a century of service, we decode its evolution from a WWI support group to a modern pillar for today's veterans.